Quotient
-
Accelerate advancement of new medicines
Bend Research and Quotient Clinical are entering into a nonexclusive collaboration that can speed the advance of compounds to clinical trials and expand options for drug delivery. The collaboration combines Bend Research’s advanced drug formula…
Quotient | 04 December 2010
-
Quotient opens new radiochemistry facility
Quotient Bioresearch has opened a new radiochemistry facility in Cardiff, UK, with a ceremony including a VIP opening by the first minister of Wales, Carwyn Jones. The new facility, named “The Old Glassworksâ€, represents a £15 million (US$23…
Quotient | 27 September 2010
-
Quotient opened new facility
Quotient Bioresearch , a provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, announced that its new radiochemistry facility in Cardiff, UK is fully operational and t…
Quotient | 28 June 2010
-
Quotient Bioresearch Announces Webinar Series
Quotient Bioresearch has announced an educational webinar series entitled "14C Enabled Drug Development in Pharmaceutical R&D." The webinars will consist of scientific presentations from industry experts focused on a range of drug development act…
Quotient | 23 April 2010
-
Quotient Bioresearch Launches Website
Quotient Bioresearch has announced the launch of its company website. The website highlights the company's key focus areas of Chemistry and Metabolism, Clinical and Bioanalytical Sciences and provides visitors with information on a range of servi…
Quotient | 11 February 2010
-
Quotient Clinical Demonstrates Drug Product Optimization with Integrated Platform
Quotient Clinical has announced the availability of a white paper demonstrating the advanced capabilities of the RapidFact approach: an integrated formulation development, manufacture and clinical testing service. The service can be used to optim…
Quotient | 15 January 2010
-
Quotient Clinical Receives MHRA Accreditation
Quotient Clinical has been awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA). This confirms that the company is qualified to perform the full range of Phase I trials, including First-in-Human (FIH…
Quotient | 01 August 2009























